MS4A1 and diffuse large B-cell lymphoma: A study showing superiority of Pola + R-CHP over CHOP therapy for previously untreated CD20-positive DLBCL with an IPI score of 2 showed that Pola + R-CHP delivered superior PFS (A risk ratio of 0.73 [95% CI: 0.57–0.95; p = 0.02] was obtained for progression, relapse, or death) as compared with R-CHOP regimens.